I / we must be missing something here. Phase 2 complete raising...

I / we must be missing something here.
Phase 2 complete raising CD34 by 1.5 times over 8 weeks (is that good enough for commercial viability or is this a positive indication where extended tests now required).
Is there a similar existing drug currently licensed potentially preventing the original application of ALT1102 to be registered (this may explain why partnerships not on the table.
What was the target market for MS treatment
With potential to license under ODA (due to other application with stem cells) would this mean both applications/vendors could now fast track through ODA or MS therapy still to be trialled via lengthy FDA process.
All of a sudden, ALT 1102 looks more promising than Alt1103 given efficacy / safety proven.
Why are we trading at this level???